E2F Transcription Factor 8 (E2F8) Antibody

Background

E2F8 is another atypical member of the E2F family that functions as a transcriptional repressor, particularly during the late stages of the cell cycle. Like E2F7, E2F8 contains two DNA-binding domains but lacks a transactivation domain, allowing it to bind and repress E2F target genes involved in cell proliferation, DNA replication, and mitosis. E2F8 is upregulated during the G2/M phase and works in conjunction with E2F7 to suppress aberrant cell cycle progression and regulate genomic stability. E2F8 is critical for embryonic development, angiogenesis, and placental formation, where it regulates the proliferation of endothelial cells and trophoblasts. Dysregulation of E2F8 has been linked to cancer progression, as its overexpression promotes tumor growth, metastasis, and chemoresistance. Knockout models reveal defects in placental vascularization, embryonic lethality, and impaired cell cycle regulation, emphasizing its importance in cell cycle control, development, and cancer biology.